Rocket Healthcare , a company specializing in artificial intelligence (AI)-based regenerative treatment platforms, announced on the 3rd that it had given a lecture on the topics of “AI Hyper-Personalized Customized Organ Regeneration Platform” and “Regenerative Niche (Soil) Theory” at the invitation of the National Institute of Health of the Korea Disease Control and Prevention Agency. This special lecture was given directly by CEO Seok-Hwan Yoo to the chronic disease and stem cell research team of the National Institute of Health.
CEO Yoo said, “Currently, the bio industry is focusing on the ‘seed theory’ that removes specific pathogens or factors, but this has limitations in organ regeneration due to metabolic diseases and chronic diseases,” and explained, “Rocket Healthcare’s ‘AI organ regeneration soil theory’ is the best alternative to solve this problem.”
Rocket Healthcare's 'organ regeneration soil theory' combines existing biotechnology with AI, bioprinting, autologous cell-based regenerative bioink, bio-electricity, and bio-mechanical systems to create a hyper-personalized customized environment optimized for patients. This makes innovative organ regeneration treatment possible.
Rocket Healthcare is achieving innovative results in skin (diabetic foot), cartilage (osteoarthritis), and kidney (chronic kidney disease) regeneration treatments through the world's first hyper-personalized organ regeneration platform. In particular, it has achieved a regeneration rate of over 90% and treatment cost reduction compared to existing treatments with an approach tailored to each patient's individual treatment environment. Rocket Healthcare has obtained US FDA and European CE certification, and plans to complete approval and registration in 16 countries by 2024. In 2023, it recorded sales of KRW 12.4 billion, showing rapid sales growth of over 30-40% on average per year.
In this lecture, CEO Yoo introduced successful cases of long-term regenerative treatment clinical trials conducted in the U.S., Europe, and Asia, and said, “Our innovative treatment will change the paradigm of the existing pharmaceutical industry and medical community.” He also said, “Disease prediction and precision treatment strategies utilizing AI and the cloud will reduce the burden on the medical insurance system and improve the quality of life of patients.” He added, “We will continue to provide hope to patients with incurable diseases through innovative medical technologies.”
You must be logged in to post a comment.